Home Cart Sign in  
Chemical Structure| 148849-67-6 Chemical Structure| 148849-67-6

Structure of Ivabradine HCl
CAS No.: 148849-67-6

Chemical Structure| 148849-67-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ivabradine HCl is an HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine HCl has anti-seizure, anti-ischemic, and anti-anginal activities and can be used in research and treatment related to heart rate control.

Synonyms: Ivabradine (hydrochloride); S 16257; Ivabradine hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ivabradine HCl

CAS No. :148849-67-6
Formula : C27H37ClN2O5
M.W : 505.05
SMILES Code : Cl[H].COC1=CC2=C(CC(=O)N(CCCN(C)C[C@H]3CC4=CC(OC)=C(OC)C=C34)CC2)C=C1OC
Synonyms :
Ivabradine (hydrochloride); S 16257; Ivabradine hydrochloride
MDL No. :MFCD00929899
InChI Key :HLUKNZUABFFNQS-ZMBIFBSDSA-N
Pubchem ID :3045381

Safety of Ivabradine HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Ivabradine HCl

GPCR

Isoform Comparison

Biological Activity

Target
  • Adrenergic Receptor

In Vitro:

Cell Line
Concentration Treated Time Description References
SAN myocytes 1 µM To evaluate the effect of Ivabradine on the spontaneous beating rate of SAN cells, results showed Ivabradine reduced the beating rate in control cells but had no effect on mutant cells. PMC4207211
HEK293 cells 30 μM Assess the current properties of HCN4 channels under AP clamp PMC8285948
Murine sinoatrial node myocytes 30 μM 120 seconds Evaluate the blocking effect of ivabradine on If current PMC8285948
MCF-10A 5 µM 2 weeks PMC8567035
MDA-MB-453 5 µM 2 weeks Suppressed cell proliferation PMC8567035
MDA-MB-231 5 µM 2 weeks Suppressed cell proliferation PMC8567035
SAN pacemaker cells 3 or 10 µM To evaluate the inhibitory effect of Ivabradine on If current in SAN cells, showing similar inhibition in both control and mutant groups. PMC2715536

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Type 1 and Type 2 diabetes models Intraperitoneal injection 2.5 mg/kg, 5 mg/kg, 10 mg/kg Single or multiple injections Ivabradine significantly reversed mechanical hypersensitivity in diabetic mice in a dose-dependent manner. Multiple injections completely restored pain thresholds to pre-diabetic levels. PMC5720342
Mice Diabetic mouse model Oral 20 mg/kg/day Once daily for 4 weeks To investigate the effect of selective heart rate reduction on cardiovascular function and ventricular-arterial coupling in a diabetic mouse model. Results showed that Ivabradine improved vascular stiffness and left ventricular systolic and diastolic function. PMC3858102
Mice Swim training model Oral 7.5 mg Single dose To assess the effect of Ivabradine on heart rate PMC5636198
Mice Ncx1−/− mice 30 µM To investigate the effect of Ivabradine on the automaticity of SAN cells in Ncx1?/? mice, results showed that under basal conditions, Ivabradine similarly reduced SAN cell automaticity in both Ncx1?/? and control mice; however, after isoproterenol stimulation, SAN cells from Ncx1?/? mice were significantly more sensitive to Ivabradine PMC3562595
Mice HHCN4-AYA transgenic mice Intraperitoneal injection 6 mg/kg Single dose To evaluate the effect of Ivabradine on heart rate, results showed Ivabradine reduced heart rate in control mice but had no effect on mutant mice. PMC4207211
Mice Cardiac-specific TRPM7 knockout mice 3 mg/kg and 6 mg/kg KOαMHC-Cre mice were less sensitive to the negative chronotropic effects of ivabradine compared to wild-type mice PMC3740880
Mice Atrial-specific NCX knockout mice Perfusion 3 μM Suppressed NCX KO SAN automaticity, reducing burst firing activity PMC4534240
Nude mice MDA-MB-231 xenograft model Subcutaneous injection 15 mg/kg Once daily for 4 weeks Significantly reduced tumor volume PMC8567035
Mice Conditional hHCN4–573X transgenic mice Intraperitoneal injection 3 or 6 mg/kg Single dose, observed for 3 hours To assess the effect of Ivabradine on heart rate, showing significant reduction in controls but no effect in mutants. PMC2715536
Mice Oxaliplatin-induced cold hypersensitivity model Intraperitoneal injection 3 mg/kg Single injection To evaluate the effect of ivabradine on oxaliplatin-induced cold hypersensitivity, it was found that ivabradine significantly alleviated cold hypersensitivity PMC3377073

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.98mL

0.40mL

0.20mL

9.90mL

1.98mL

0.99mL

19.80mL

3.96mL

1.98mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories